Francesca Ceccherini Silberstein
Francesca Ceccherini Silberstein
Verified email at
TitleCited byYear
2017 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 24 (4), 132, 2016
European recommendations for the clinical use of HIV drug resistance testing: 2011 update
AM Vandamme, RJ Camacho, F Ceccherini-Silberstein, A De Luca, ...
Aids Rev 13 (2), 77-108, 2011
Characterization and structural analysis of HIV-1 integrase conservation
F Ceccherini-Silberstein, I Malet, R D’Arrigo, A Antinori, AG Marcelin, ...
AIDS Rev 11 (1), 17-29, 2009
Cytomegalovirus coinfection is associated with an increased risk of severe non–AIDS-defining events in a large cohort of HIV-infected patients
M Lichtner, P Cicconi, S Vita, A Cozzi-Lepri, M Galli, S Lo Caputo, ...
The Journal of infectious diseases 211 (2), 178-186, 2014
Functional characterization of substance P receptors on cultured human spinal cord astrocytes: Synergism of substance P with cytokines in inducing interleukin‐6 and …
C Palma, L Minghetti, M Astolfi, E Ambrosini, F Ceccherini Silberstein, ...
Glia 21 (2), 183-193, 1997
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors
V Svicher, T Sing, MM Santoro, F Forbici, F Rodríguez-Barrios, A Bertoli, ...
Journal of virology 80 (14), 7186-7198, 2006
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 …
A Cozzi-Lepri, M Noguera-Julian, F Di Giallonardo, R Schuurman, ...
Journal of antimicrobial chemotherapy 70 (3), 930-940, 2014
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
V Cento, C Mirabelli, R Salpini, S Dimonte, A Artese, G Costa, F Mercurio, ...
PloS one 7 (7), e39652, 2012
Diminished rev-mediated stimulation of human immunodeficiency virus type 1 protein synthesis is a hallmark of human astrocytes
E Ludwig, F Ceccherini-Silberstein, J van Empel, V Erfle, M Neumann, ...
Journal of virology 73 (10), 8279-8289, 1999
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure
F Ceccherini-Silberstein, F Erba, F Gago, A Bertoli, F Forbici, ...
Aids 18 (12), 11-19, 2004
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to …
F Ceccherini-Silberstein, V Svicher, T Sing, A Artese, MM Santoro, ...
Journal of virology 81 (20), 11507-11519, 2007
Upregulated expression of interleukin-8, RANTES and chemokine receptors in human astrocytic cells infected with HIV-1
M Cota, A Kleinschmidt, F Ceccherini-Silberstein, F Aloisi, M Mengozzi, ...
Journal of neurovirology 6 (1), 75-83, 2000
Non-AIDS defining cancers in the D: A: D Study-time trends and predictors of survival: a cohort study
SW Worm, M Bower, P Reiss, F Bonnet, M Law, G Fätkenheuer, ...
BMC infectious diseases 13 (1), 471, 2013
Emerging patterns and implications of HIV-1 integrase inhibitor resistance
AM Geretti, D Armenia, F Ceccherini-Silberstein
Current opinion in infectious diseases 25 (6), 677-686, 2012
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors
V Svicher, F Ceccherini-Silberstein, F Erba, M Santoro, C Gori, ...
Antimicrobial agents and chemotherapy 49 (5), 2015-2025, 2005
Understanding HIV compartments and reservoirs
V Svicher, F Ceccherini-Silberstein, A Antinori, S Aquaro, CF Perno
Current HIV/AIDS Reports 11 (2), 186-194, 2014
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors
I Malet, L Gimferrer Arriaga, A Artese, G Costa, L Parrotta, S Alcaro, ...
Journal of Antimicrobial Chemotherapy 69 (8), 2118-2122, 2014
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection
V Svicher, V Cento, M Bernassola, M Neumann-Fraune, F Van Hemert, ...
Antiviral research 93 (1), 86-93, 2012
Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing
D Armenia, I Vandenbroucke, L Fabeni, H Van Marck, V Cento, R D’Arrigo, ...
Journal of Infectious Diseases 205 (4), 557-567, 2012
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018
MC Sorbo, V Cento, VC Di Maio, AYM Howe, F Garcia, CF Perno, ...
Drug Resistance Updates 37, 17-39, 2018
The system can't perform the operation now. Try again later.
Articles 1–20